Amyloid and tau biomarkers are used to support a diagnosis of AD in research studies, and the National Institute on Aging-Alzheimer’s Association (NIA-AA) framework also recommends inclusion of these biomarkers for earlier identification of individuals in preclinical or prodromal stages of the disease (Jack et al. 2018). The gene discussed is MAPT; the disease is Alzheimer disease.